Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?

ABSTRACT:

Background

Lung stereotactic ablative radiotherapy (SABR) is associated with low morbidity, however there is an increased risk of treatment-related toxicity in tumors directly abutting or invading the proximal bronchial tree, termed 'ultra-central' tumors. As there is no consensus regarding the optimal radiotherapy treatment regimen for these tumors, we performed a modeling study to evaluate the trade-offs between predicted toxicity and local control for commonly used high-precision dose-fractionation regimens.

Methods

Ten patients with ultra-central lung tumors were identified from our institutional database. New plans were generated for 3 different hypofractionated schemes: 50 Gy in 5 fractions, 60 Gy in 8 fractions and 60 Gy in 15 fractions. For each regimen, one plan was

SUBMITTER: Murrell DH 

PROVIDER: S-EPMC5880025 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature